Abstract: A pharmaceutical composition comprising an isoxazoline compound complexed with a cyclodextrin such as hydroxy-propyl-cyclodextrin and combined in a dry (anhydrous) composition with polypowder. The composition can be a mixture of isomers, an enriched mixture of a specific enantiomer or a single enantiomer.
Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to TREM2. The invention also relates to multimeric binding complexes which comprise at least two of said bicyclic peptide ligands. The invention also includes pharmaceutical compositions comprising said peptide ligands and multimeric binding complexes and the use of said peptide ligands, multimeric binding complexes and pharmaceutical compositions in preventing, suppressing or treating a disease or disorder mediated by TREM2.
Type:
Grant
Filed:
March 18, 2022
Date of Patent:
February 20, 2024
Assignee:
BicycleTx Limited
Inventors:
Paul Brennan, Amy Brown, Liuhong Chen, John Davis, Yuliya Demydchuk, Donatella Di Rienzo, Ellen Gowans, Rama McCrory, Emma Mead, Emma Murphy, Mike Rigby, Michael Skynner, Tom Smith, Steven Stanway
Abstract: Provided is a composition for preventing hair loss or promoting hair development, comprising, as an active ingredient, phellandrene or a pharmaceutically acceptable salt thereof. More specifically, provided is a pharmaceutical composition, a quasi-drug composition, a cosmetic composition, or a health functional food composition, for preventing hair loss, treating hair loss, promoting hair development, or promoting hair growth, the composition comprising phellandrene or a salt thereof as an active ingredient.
Type:
Grant
Filed:
October 25, 2018
Date of Patent:
February 20, 2024
Assignee:
INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.
Type:
Grant
Filed:
August 8, 2023
Date of Patent:
February 13, 2024
Assignee:
Flamel Ireland Limited
Inventors:
Jordan Dubow, Hervé Guillard, Claire Mégret, Jean-François Dubuisson
Abstract: Apixaban pharmaceutical formulation is provided. Also provided is a use of the apixaban formulation in treatment of a thromboembolic disorder.
Type:
Grant
Filed:
April 15, 2019
Date of Patent:
February 13, 2024
Assignees:
Bristol-Myers Squibb Company, Pfizer Inc.
Inventors:
Sherif Ibrahim Farag Badawy, Timothy D. Stevens, Daniel Kuntz, Brett Waybrant
Abstract: Provided herein is a method of treating medulloblastoma or glioblastoma in a subject by administering to the subject a PI3K activator (e.g., thymosin ?-4 or a derivative thereof) and one or more chemotherapeutic agents and/or radiation. The combination therapy is effective in the treatment of medulloblastoma or glioblastoma characterized by cells with elevated p53 levels.
Abstract: Disclosed are methods of treating, inhibiting, or preventing the development of, a food allergy in a patient by administering a therapeutically effective amount of a thiol isomerase inhibitor to a patient in need thereof. Also disclosed are methods for treatment of other allergic diseases and inflammatory diseases.
Abstract: A cell penetrating peptide (CPP) according to the present invention is a novel cationic cell penetrating peptide that can effectively transport a biologically active molecule by passing through a cell membrane even when a biologically active molecule is bound thereto, and compared with conventional CPPs, it has excellent cell permeability enabling the transport of a biologically active molecule into cells, and the delivered biologically active molecule may effectively maintain its activity in cells. Accordingly, the CPP of the present invention may be very useful in various fields including cosmetics, diagnostics, drug delivery systems, recombinant protein vaccines, DNA/RNA therapeutics, and gene and protein therapy.
Type:
Grant
Filed:
July 22, 2022
Date of Patent:
January 30, 2024
Assignee:
CELLTROY CO., LTD.
Inventors:
Chang-Kyu Oh, Jae-Ho Lee, Soon-Ik Park, Jeong-Ho Park, Won-Jin Park, Yun-Chu Cho
Abstract: Methods of preparing protein films in the presence of organofluorine compounds are provided that can produce protein films that retain the solution phase characteristics of the proteins. The protein films can be coatings for medical devices.
Type:
Grant
Filed:
November 5, 2018
Date of Patent:
January 30, 2024
Assignee:
University of Massachusetts
Inventors:
Li-Sheng Wang, Sanjana Gopalakrishnan, Vincent M. Rotello
Abstract: The present application provides stable peptide-based IDO1 capture agents and methods of use as detection, imaging, diagnostic and therapeutic agents. The application further provides methods of manufacturing IDO1 imaging agents.
Abstract: The invention relates to functionalized polymers, a process for producing functionalized polymers and the use of functionalized polymers, especially in the field of personal care.
Abstract: The present invention relates to a tablet composition for oral administration of abiraterone acetate, particularly to pharmaceutical granulates and tablets giving immediate release of abiraterone acetate in the stomach.
Type:
Grant
Filed:
January 25, 2019
Date of Patent:
January 9, 2024
Assignee:
Synthon B.V.
Inventors:
Sara Fradera Gelabert, Manuel Gago Guillan, Lisardo Alvarez Fernandez, Rohit Kumar
Abstract: Peptide-immuno-oncology agent complexes (“peptide-I/O complexes”) that can home, target, migrate to, are directed to, are retained by, accumulate in, penetrate, or bind to the tumor microenvironment, tumor tissues, or cells or compartments or cytosol of cells thereof, or any combination thereof, are disclosed. Additionally disclosed are peptide-I/O complexes that can cross the blood-brain barrier. Pharmaceutical compositions and uses for peptide-I/O complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of an immuno-oncology agent (“I/O”) to the tumor microenvironment. Targeted compositions of the disclosure can deliver peptide-I/O complexes to target regions, tissues, structures or cells targeted by the peptide.
Type:
Grant
Filed:
December 18, 2018
Date of Patent:
January 9, 2024
Assignee:
BLAZE BIOSCIENCE, INC.
Inventors:
Natalie Winblade Nairn, Julia Novak, Kenneth Grabstein, Dennis Miller, Greg T. Hermanson, Scott R. Presnell, Mark Stroud
Abstract: Disclosed is a polypeptide having a phase transition behavior, wherein the polypeptide consists of a Val-Pro-Gly-Xaa-Gly pentapeptide repeat or a Val-Pro-Ala-Xaa-Gly) pentapeptide repeat, and the polypeptide includes a [Val-Pro-Gly-Xaa-Gly]n or a [Val-Pro-Ala-Xaa-Gly]n (SEQ ID NO:2) pentapeptide repeat. In addition, the present invention provides a multi-stimuli polypeptide composed of polypeptide-calmodulin-polypeptide having a phase transition behavior and a hydrogel prepared using the same. A dynamic protein hydrogel according to the present invention may be used as a drug carrier, as a scaffold for tissue engineering or as a kit for tissue or organ regeneration.
Type:
Grant
Filed:
June 8, 2021
Date of Patent:
January 9, 2024
Assignee:
Industry-University Cooperation Foundation Hanyang University Erica Campus
Inventors:
Dong Woo Lim, Jae Sang Lee, Min Jung Kang
Abstract: This disclosure is directed to ibudilast higher dosage oral formulations, such as tablet or capsule formulations, and the corresponding methods of treatment.
Type:
Grant
Filed:
September 21, 2020
Date of Patent:
January 9, 2024
Assignee:
MediciNova, Inc.
Inventors:
Kazuko Matsuda, Federico Carlos Aréjola Gaeta
Abstract: The present invention relates generally to the field of bone graft substitutes and methods for making the same, particularly the invention relates to bone graft substitutes for use in dental or orthopaedic implants. The bone graft substitutes described herein comprise a silicate based material. The silicate based material is a silicate network with a porous structure. The silicate network has one or more metal cations incorporated therein. Preferably a phosphate is also incorporated into the silicate network. The bone graft substitute may have a low density, preferably a density of less than 1.1 g/cm3. The bone graft substitute may be an aerogel or a cryogel.
Abstract: Aspects and embodiments of the present invention relate to the treatment of neurological disorders such as for example, Alzheimers disease and Parkinsons disease. Particularly, certain embodiments relate to GIP/GLP-1 co-agonist peptides for use in the treatment of these two neurological disorders. Also included in the present invention are inter alia pharmaceutical compositions comprising the GIP/GLP-1 co-agonist peptides, together with methods of treating such disorders as well as other subject matter.
Abstract: A skin care composition that includes a combination of palmitoyl dipeptide-7, acetyl tetrapeptide-11, other optional skin ingredients, and a dermatologically acceptable carrier. The combination of peptides synergistically improves cellular ATP level and/or upregulates the expression of peroxisome proliferator activated receptor alpha and/or methylsterol monooxygenase 1 to help provide improved skin health and appearance.
Type:
Grant
Filed:
January 4, 2023
Date of Patent:
December 26, 2023
Assignee:
The Procter & Gamble Company
Inventors:
Leo Timothy Laughlin, II, Michael Joseph Flagler, Lisa Ann Mullins, Makio Tamura
Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.
Abstract: The present invention relates to a method for preparing immediate and sustained release solid dosage forms, comprising antibodies and functional fragments thereof, by solution/suspension layering, optionally coated with a delayed release coating; the solid dosage forms prepared by the method; and the use of the solid dosage forms in the topical treatment in the gastrointestinal tract of a patient.
Type:
Grant
Filed:
September 11, 2018
Date of Patent:
November 28, 2023
Assignee:
Tillotts Pharma AG
Inventors:
Felipe Varum, Laetitia Von Rochow, Carmen Goetz, Roberto Bravo